Oncotarget

Corrections:

Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice

PDF  |  How to cite

Oncotarget. 2018; 9:30472-30472. https://doi.org/10.18632/oncotarget.25791

Metrics: PDF 610 views  |   ?  

Patrick M. Reeves1, Mojgan A. Abbaslou1, Farah R.W. Kools1, Kritchai Vutipongsatorn1, Xiaoyun Tong1, Christina Gavegnano2, Raymond F. Schinazi2 and Mark C. Poznansky1

1 Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA 02129, USA
2 Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA

Published: July 13, 2018

This article has been corrected: The correctly spelled author name is given below:

Christina Gavegnano

Original article: Oncotarget. 2017; 8:94040-94053. DOI: https://doi.org/10.18632/oncotarget.21541.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25791